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Abstract
Background—Universal 2-dose varicella vaccination was recommended in 2006 to further 
reduce varicella disease burden. This study examined 2-dose varicella vaccine effectiveness (VE) 
and rash severity in the setting of school-associated varicella outbreaks.
Methods—A case control study was conducted from January 2010 to May 2011 in all West 
Virginia public schools. Clinically diagnosed cases from varicella outbreaks were matched with 
classmate controls. Vaccination information was collected from school, health department and 
healthcare provider immunization information systems.
Results—Among the 133 cases and 365 controls enrolled, VE against all varicella was 83.2% 
[95% confidence interval (CI): 69.2%–90.8%] for 1-dose of varicella vaccine and 93.9% (95% CI: 
86.9%–97.1%) for 2-dose; the incremental VE (2-dose vs. 1-dose) was 63.6% (95% CI: 32.6%–
80.3%). In preventing moderate/severe varicella, 1-dose varicella vaccine was 88.2% (95% CI: 
72.7%– 94.9%) effective, and 2-dose vaccination was 97.5% (95% CI: 91.6%–99.2%) effective, 
with the incremental VE of 78.6% (95% CI: 40.9%–92.3%). One-dose VE declined along with 
time since vaccination (VE = 93.0%, 88.0% and 81.8% in <5, 5–9 and ≥10 years after vaccination, 
P = 0.001 for trend). Both 1- and 2-dose breakthrough cases had milder rash than unvaccinated 
cases (<50 lesion: 24.6%, 49.1% and 70.0% in unvaccinated, 1-dose and 2-dose cases, P < 0.001), 
and no severe disease was found in 2-dose cases.
Conclusions—Two-dose varicella vaccination is highly effective and confers higher protection 
than a 1-dose regimen. High 2-dose varicella vaccination coverage should maximize the benefits 
of the varicella vaccination program and further reduce varicella disease burden in the United 
States.
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Varicella (chickenpox) is a highly contagious disease caused by the varicella zoster virus 
(VZV), which, in the absence of vaccination, is a universal infection acquired mainly in 
childhood. Prior to introduction of varicella vaccine in 1995, an estimated 4 million varicella 
cases, 11,000 hospitalizations and 100 deaths occurred each year in the United States.1 Since 
introduction of 1-dose varicella vaccination in the United States, dramatic declines were 
documented in the number of varicella cases,2 outbreaks,3 varicella-related hospitalizations 
and deaths.4,5 However, albeit smaller in size and shorter in duration, varicella outbreaks 
continued to occur in school and daycare settings with high 1-dose varicella vaccination 
coverage6-9; therefore, a routine 2-dose varicella vaccination was recommended in 2006 for 
school-aged children and a catch-up vaccination for children of all ages who lacked 
evidence of immunity.10
The 2-dose program appears to have been rapidly implemented in the United States in the 
first 5 years since it was recommended. For the 2012–2013 school-year, median 2-dose 
varicella vaccination coverage among the 36 states and District of Columbia requiring and 
reporting 2 doses was 93.8% (range: 84.6% in Colorado to ≥99.9% in Mississippi); 14 
reported coverage ≥95%.11,12 There are limited data on the effectiveness of the 2-dose 
varicella vaccine regimen and very limited numbers of 2-dose breakthrough cases reported, 
thus more data are needed to describe 2-dose vaccine effectiveness (VE) and rash 
presentations of 2-dose breakthrough varicella. Therefore, a case control study was 
conducted in West Virginia public schools during 2010 and 2011 to evaluate 1-dose, 2-dose 
and incremental varicella VE and characterize 2-dose breakthrough varicella.
MATERIALS AND METHODS
Study Population and Data Collection
West Virginia Department of Health and Human Resources was one of 6 sites to receive 
American Recovery and Reinvestment Act funding through the Centers for Disease Control 
and Prevention to conduct school-based varicella outbreak surveillance from January 2010 
to December 2011. In West Virginia, 2-dose varicella vaccination became school entry 
requirement in 2008, and the vaccination coverage reached 88.9% among children enrolled 
in kindergartens in 2011–12 school year.13 From January to May 2010 and September 2010 
to May 2011, the 220 school nurses serving all 688 public elementary, middle/junior and 
high schools in West Virginia reported via monthly electronic surveys whether any varicella 
outbreak had occurred in the school during the previous month and, if any had been 
detected, the number of outbreak-associated cases. A case of varicella was defined as an 
acute maculopapulovesicular rash without other apparent cause14 in a West Virginia public 
school student 5 through 18 years of age. Breakthrough varicella was defined as a case that 
developed >42 days after vaccination. A school outbreak was defined as 3 or more cases of 
varicella, with each case having rash onset within 1 incubation period (21 days) of the 
previous case within the same school. Whenever possible, lesion or scab samples from 
outbreak-associated cases were collected and sent to Centers for Disease Control and 
Prevention for VZV testing using a polymerase chain reaction assay to detect the presence 
of wild-type VZV DNA; an inadequate specimen was defined as one in which neither VZV 
DNA nor β-Actin (the control) was detected.
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For each case, an alphabetic list of classmates was provided by school nurses regardless of 
age and immunization status. The first 5 classmates on the list were contacted initially, and 
the remainders were contacted only if <3 eligible controls out of the first 5 classmates 
contacted were enrolled. The enrollment ended when 3 controls were enrolled or all eligible 
classmates were contacted. A control was only enrolled in the study once. School nurses 
and/or West Virginia Department of Health and Human Resources staff used a standard 
form to collect demographic, clinical and epidemiologic data from cases and controls after 
obtaining consent from parents/guardians. A study nurse trained school nurses on 
recognizing varicella, including mild breakthrough varicella, and categorizing rash severity. 
Case and control candidates with prior varicella history based on physician diagnosis or 
parental report were excluded from VE analyses. In addition, children who were receiving 
immunosuppressive therapy, had an acquired or congenital immune deficiency, had 
contraindication to varicella vaccine or had received varicella vaccine within 42 days of rash 
onset (for cases) or date of rash onset of the matched case (for controls) were not eligible for 
participation. School nurses categorized rash severity based on the number of skin lesions 
observed (<50, 50–249, 250–500 and >500) as mild (<50 lesions), moderate (50–500), 
severe (>500) or moderate/severe (≥50). Any hospitalization or serious complication such as 
secondary bacterial infection or neurologic complications would be recorded; sequelae such 
as scarring were not collected. Vaccination dates were verified using the West Virginia 
Statewide Immunization Information System, West Virginia Education Information System 
or participants’ physician offices. Valid doses of varicella vaccine were defined as dose 1 
administered not earlier than 4 days before age 12 months, and dose 2 administered at least 
28 days after dose 1. The type of varicella vaccine received was not recorded, and only 2 
varicella vaccines (Varivax and ProQuad) from Merck & Co., Inc. (Whitehouse Station, NJ) 
were available in the United States.
Statistical Analyses
The date of rash onset in the case was used to assess vaccination status of the matched 
controls. Varicella VE was defined as [1 − odds ratio] ×100%; odds ratios were calculated 
using conditional logistic regression. The unvaccinated subjects served as the reference 
group for 1-dose and 2-dose VE calculation. The 1-dose recipients were the reference group 
for calculating incremental VE, defined as the additional protection conferred by 2-dose 
vaccination compared with 1-dose vaccination. Changes in VE by time since vaccination 
were calculated using previously described methods.15 Time since vaccination was defined 
as the time interval between the date of the most recently administered valid dose of 
varicella vaccine and the rash onset date. The trend of VE changes along time since 
vaccination was assessed with modification on the cited method15 by assigning ordered 
values to the categories of time since vaccination by length of time since vaccination and the 
unvaccinated were the reference group. The distribution of categorical or continuous 
variables between cases and controls were examined with Mantel–Haenszel χ2 or Student t 
test, respectively. All analyses were performed with SAS version 9.3 (SAS Inc., Cary, NC).
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From January 2010 through May 2011, 30 varicella outbreaks with a total of 266 cases were 
reported from 30 schools in 17 counties. Classmate contact information, used for identifying 
controls, was not available for 13 outbreaks (103 cases). The remaining 163 cases from 17 
outbreaks were contacted for the case control study; they did not differ significantly from 
the non-participating cases by age (11.1 vs. 11.1 years, P = 0.78), sex (male: 52.1% vs. 
56.3%, P = 0.51) or rash severity (mild rash: 41% vs. 40%, P = 0.92). The characteristics of 
the outbreaks from which the participating cases were identified did not differ significantly 
from those of the non-participating cases in average number of cases per outbreak (9.6 vs. 
7.9, P = 0.49), or proportion of breakthrough cases in the outbreak (61.4% vs. 53.3%, P = 
0.22).
Of the 163 cases, 133 (86.9%) were enrolled in the study. Of the 30 cases excluded, 10 cases 
had prior disease history, 8 cases lacked immunization records and the parents of 12 cases 
refused participation. Of 12 cases with specimens collected, 11 were confirmed as varicella, 
and 1 had an inadequate specimen. Over half the cases (70, 53.0%) had moderate rash, 7 
(5.3%) had severe rash (none of them were 2-dose recipients) and 55 (41.7%) had mild rash. 
None of the cases developed complications or were hospitalized due to varicella. No 
vaccinated cases had rash onset within 42 days after receipt of varicella vaccine.
Among 816 students contacted for enrollment as controls, parents/guardians of 346 students 
(42.4%) did not respond, 105 were ineligible for participation due to prior varicella history 
(n = 83), missing vaccination status (n = 18), or receipt of varicella vaccine within 42 days 
of the first case of the outbreak (n = 4). The remaining 365 eligible students were enrolled as 
controls producing a total of 498 participants, with an average of 3 matched controls per 
case (range: 1–5 controls/case). The majority of participants were elementary school 
students (305, 61.2%), with half of the participants (246, 49.4%) being female with an 
average age of 11 years (range 5.3–18.7 years). There was no difference between cases and 
controls in age and sex (P = 0.27 and 0.58, respectively), but proportionally more cases were 
unvaccinated and more controls had received 2 doses of varicella vaccine (P < 0.001). Cases 
had longer time intervals since last vaccination than controls (7.5 vs. 5.7 years, P < 0.001), 
were younger at the time of 2-dose vaccination (6.2 vs. 8.2 years, P = 0.007) and 
proportionally more received the second dose of vaccine at <6 years of age (60.0% vs. 
33.1%, P = 0.03). There were no differences between cases and controls in age at the time of 
receipt of the first dose of varicella vaccine or interval between 1-dose and 2-dose varicella 
vaccine (P = 0.31 and 0.09, respectively) (Table 1).
Varicella Vaccine Effectiveness
The effectiveness against all varicella was 83.2% [95% confidence interval (CI): 69.2%–
90.8%] for 1-dose of varicella vaccine and 93.9% (95% CI: 86.9%–97.1%) for 2-dose; the 
incremental VE (2-dose vs. 1-dose) was 63.6% (95% CI: 32.6%–80.3%) (Table 2). In 
preventing moderate/severe varicella, 1-dose varicella vaccine was 88.2% (95% CI: 72.7%–
94.9%) effective, and 2-dose vaccination was 97.5% (95% CI: 91.6%–99.2%) effective, 
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with an incremental VE of 78.6% (95% CI: 40.9%–92.3%). One-dose VE decreased by time 
since vaccination: VE was 93.0% within 5 years after vaccination, 88.0% from 5 to 9 years 
after vaccination, and 81.8% with ≥10 years after vaccination (P = 0.001 for trend) (Table 
3). No change in 2-dose VE was observed along with time since vaccination (92.8%, 87.8% 
and 50.7% for those who received vaccine at ≤2 years, 3–5 years and >5 years before, P = 
0.73 for trend) (Table 3). There was no difference in 1-dose VE by age at first dose (<15 
months vs. ≥15 months, P = 0.11), and 2-dose VE by age at second dose (<6 years vs. ≥6 
years, P = 0.88) or by length of time interval between 1-dose and 2-dose vaccination (≤5 
years vs. >5 years, P = 0.94).
Rash Presentation
Among the 132 cases with available data, the rash severity decreased along with doses of 
vaccination received. The proportion of mild rash decreased from 70% in 2-dose cases, 
49.1% in 1-dose cases, to 24.6% in unvaccinated cases, while the proportion of severe rash 
increased from 0% in 2-dose cases, 3.6% in 1-dose cases, to 8.8% in unvaccinated cases (P 
< 0.001) However, there was no overall difference in rash severity between 1-dose and 2-
dose vaccinated cases (P = 0.38), even though no severe rash was observed in 2-dose cases 
in contrast to 3.6% in 1-dose cases (Table 4).
DISCUSSION
In varicella school outbreaks reported during 2010–2011, 2 doses of varicella vaccine 
conferred greater protection against all varicella and moderate/severe varicella than a single 
dose. Moreover, though 2-dose breakthrough varicella occurred, the majority of those cases 
were mild with no cases of severe rash observed among 2-dose vaccine recipients. These 
data, in addition to declines in varicella incidence and the reduced number and size of 
varicella outbreaks observed since the initiation of the 2-dose varicella vaccination regimen, 
provide evidence of the greater effectiveness of 2-dose varicella vaccination compared to the 
single dose regimen.16-18
This study adds to data on 2-dose varicella vaccine effectiveness. A pre-licensure, 
randomized clinical trial comparing 1-dose versus 2-dose varicella vaccine regimens using a 
historical varicella attack rate demonstrated a 2-dose VE of 98%.19 Three subsequent case 
control studies of laboratory-confirmed cases reported similarly high 2-dose VE estimates of 
98% in a study conducted in Connecticut during 2006–2010, 97% from a study conducted in 
Spain during 2010–2012, and 94% in a study conducted in Germany during 2008–2010.20-22 
Our 2-dose VE estimate of 94% is similar to these estimates. Use of laboratory-confirmed 
case definitions in vaccine effectiveness studies results in increases in case specificity and 
higher VE estimates.23 The single published 2-dose varicella VE of <90% was reported 
from an investigation of a varicella outbreak in a school complex in Arkansas in which 2 
doses of varicella vaccine did not appear to confer additional protection compared to 1-
dose.24 The reasons for the lower 2-dose VE reported from the Arkansas outbreak are 
unclear; however, it is likely that circulation of the virus has declined since that study was 
conducted and routine 2-dose varicella vaccination has been widely implemented.11 The 
rapid take-up of 2-dose varicella vaccine in West Virginia, evidenced in the high vaccination 
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coverage in the controls of our study as well as high coverage in children in West Virginia 
kindergartens,12 likely resulted in lower circulation of the virus and contributed to the 
observed higher VE. The incremental VE in the current study of 64% is similar to the 69.9% 
calculated from the clinical trial, within in the range of the reported 74% from case control 
study in Spain,19,21 but lower than the 94.7% calculated from the case control study in 
Connecticut.20 The higher incremental VE estimate from the Connecticut study may be 
explained in part by the lack of 2-dose cases available for the analysis.20 To the best of our 
knowledge, this is the first since the clinical trial to report on 2-dose varicella VE against 
moderate/severe rash,25 and the greater effectiveness of 2-dose vaccination in preventing 
moderate/severe varicella than against any varicella. The finding of greater effectiveness 
against moderate/severe varicella than against all varicella was also observed with the 1-
dose varicella vaccination effectiveness.26 In addition, the estimate of 1-dose VE of 83% in 
this study is consistent with the 1-dose varicella VE of 85% reported in the literature.26 All 
these consistencies add to the credibility of the current findings.
In contrast to some studies,27-29 our study and others30-32 have found a trend of decreasing 
VE over time. These findings may reflect true waning of vaccine protection over time or 
may represent an increased risk of exposure (and force of infection) in older compared to 
younger age groups.2,33 Between 1995 and 2010, the median age of varicella increased from 
3–5 years to 7–9 years among vaccinated cases and from 5–6 years to >15 years among 
unvaccinated cases.2,16 This changing epidemiology confounds analysis of vaccine 
effectiveness by time since vaccination. More data are needed to better understand the 
duration of protection in children after varicella vaccination, although this is increasingly 
challenging to investigate as disease circulation and risk of exposure has declined so 
substantially since vaccine introduction. Given the small number of cases and controls 
receiving 2-dose varicella vaccine >5 years before enrollment in our study, it was not 
possible to produce a reliable estimate on varicella 2-dose VE after 5 years since 
vaccination. The lack of differences in 2-dose VE by age at vaccination or length of time 
between receiving first and second doses reinforces the importance of catch-up vaccination 
at any age as an effective way to induce protection.
Similar to findings reported from clinical trials,19,25 2-dose recipients with breakthrough 
varicella appear to present with fewer lesions than in the 1-dose recipients, and none with 
severe rash was identified. The failure to detect statistically significant differences in rash 
severity between 1-dose and 2-dose breakthrough cases may be due to the rarity of severe 
breakthrough varicella and/or the small number of breakthrough cases enrolled. Given the 
limitations of current laboratory assays for confirming varicella, especially in mild 
breakthrough varicella in the 2-dose varicella vaccination era, ascertaining the full spectrum 
of breakthrough disease will be challenging. As a greater proportion of cases present with 
<50 lesions among breakthrough cases,25 it may be informative to collect more precise data 
on the numbers of lesions from cases with mild disease. Understanding the extent to which 
very mild breakthrough varicella cases are contagious34 and present a risk to susceptible 
individuals is important for ensuring that implementation of varicella control efforts is 
effective as well as the need to exclude such cases from work and school.
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Several limitations should be considered in interpreting the current findings. This study 
relied on a clinical case definition that did not require laboratory confirmation and may 
underestimate VE. The mild clinical manifestations in 1-dose and 2-dose breakthrough cases 
make misclassification possible and may lead to overreporting or underreporting of 
varicella. It can be challenging to confirm varicella by laboratory testing due to difficulties 
in collecting adequate specimens from maculopapular rashes.35 The categorization of rash 
severity used in this study was based on reports from a large number of school nurses, and 
there may have been variation in accuracy of their observations
In conclusion, both 1-dose and 2-dose varicella vaccine regimens are highly effective in 
preventing varicella, but 2-dose vaccination induces higher protection than the 1-dose 
regimen. The clinical manifestations of breakthrough varicella among 2-dose vaccinees may 
be milder than among 1-dose vaccinees, but more data are needed to better understand this 
as well as whether VE wanes over time. Full implementation of the routine 2-dose varicella 
vaccination program should result in further reductions in varicella incidence and outbreaks.
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TABLE 1
Demographic and Vaccination Characteristics Among Cases and Controls in Public School Students of West 
Virginia, 2010–2011
Cases (N = 133), n (%) Controls (N = 365), n (%) P Value
Age in years: mean (range) 10.8 (5.3–18.0) 10.5 (5.4–18.7) 0.27
Years since last dose of varicella vaccine: mean (range) 7.5 (0.7–14.4) 5.7 (0.1–14.7) <0.001
Age in months at receipt of first dose varicella vaccine: mean (range) 24.0 (12.2–139.5) 29.1 (12.0–165.1) 0.12
Age in years at receipt of second dose of varicella vaccine: mean (range) 6.2 (2.6–13.4) 8.2 (1.5–15.3) 0.007
Years between first and second dose: mean (range) 4.9 (1.6–12.1) 6.1 (0.2–13.4) 0.09
Sex 0.58
 Male 70 (52.6) 182 (49.9)
 Female 63 (47.4) 183 (50.1)
Vaccination status <0.001
 Unvaccinated 57 (42.9) 36 (9.9)
 1-dose 56 (42.1) 181 (49.6)
 2-dose 20 (15.0) 148 (40.6)
Received first dose of varicella vaccine at <15 months of age 42 (55.3) 158 (48.0) 0.31
Received second dose of varicella vaccine at age <6 years 12 (60.0) 49 (33.1) 0.03
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TABLE 2
Varicella Vaccine Effectiveness Against All Varicella and Moderate/Severe Varicella in Public School 
Students of West Virginia, 2010–2011
Cases, n (%) Controls, n (%) VE (95% CI) P Value
All varicella cases and matched controls N = 133 N = 365
 Unvaccinated 57 (42.9) 36 (9.9) Reference
  1-dose 56 (42.1) 181 (49.6) 83.2 (69.2–90.8) <0.001
  2-dose 20 (15.0) 148 (40.6) 93.9 (86.9–97.1) <0.001
  Incremental (1-dose recipients as reference) 63.6 (32.6–80.3) 0.001
Moderate/severe cases and matched controls N = 77 N = 216
 Unvaccinated 43 (55.8) 24 (11.1) Reference
  1-dose 28 (36.4) 107 (49.5) 88.2 (72.7–94.9) <0.001
  2-dose 6 (7.8) 85 (39.4) 97.5 (91.6–99.2) <0.001
  Incremental (1-dose recipients as reference) 78.6 (40.9–92.3) 0.003
VE indicates vaccine effectiveness; 95% CI, 95% confidence interval.
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TABLE 3
One-Dose and Two-Dose Varicella Vaccine Effectiveness Against All Varicella by Time Since Vaccination in 
Public School Students of West Virginia, 2010–2011
Cases, n (%) Controls, n (%) VE (95% CI) P Value P Value
Unvaccinated 57 (50.4) 36 (16.6) Reference
Years since receipt of first dose of varicella vaccine N = 56 N = 181
 <5 years 4 (3.5) 31 (14.3) 93.0 (75.0–98.1) <0.001 Reference
 5–9 years 31 (27.4) 93 (42.9) 88.0 (72.4–94.8) <0.001 0.36
 ≥10 years 21 (18.6) 57 (26.3) 81.8 (57.8–92.1) <0.001 0.15
Years since receipt of second dose of varicella vaccine N = 20 N = 148
 <3 years 7 (9.7) 65 (90.3) 92.8 (72.4–98.1) <0.001 Reference
 3–5 years 11 (12.5) 77 (87.5) 87.8 (65.1–95.8) <0.001 0.240
 >5 years 2 (25.0) 6 (75.0) 50.7 (0–97.5) 0.64 <0.001
VE indicates vaccine effectiveness; 95% CI, 95% confidence interval.
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TABLE 4
Association of Rash Severity With Vaccination Status in Varicella Cases Identified in Public School 
Outbreaks of West Virginia, 2010–2011
a
Vaccination Status
Unvaccinated, n (%) 1-Dose, n (%) 2-Dose, n (%) Overall P Value
P Value (1-Dose vs.
2-Dose Cases)
Number of lesions N = 57 N = 55 N = 20 <0.001 0.38
<50 14 (24.6) 27 (49.1) 14 (70.0)
50–249 19 (33.3) 23 (41.8) 5 (25.0)
250–500 19 (33.3) 3 (5.5) 1 (5.0)
>500 5 (8.8) 2 (3.6) 0 (0.0)
a
One case had missing information on rash severity.
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